Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Gross Profit (2017 - 2025)

Aclaris Therapeutics has reported Gross Profit over the past 9 years, most recently at $763000.0 for Q4 2025.

  • Quarterly results put Gross Profit at $763000.0 for Q4 2025, down 91.03% from a year ago — trailing twelve months through Dec 2025 was $5.7 million (down 64.0% YoY), and the annual figure for FY2025 was $5.7 million, down 63.99%.
  • Gross Profit for Q4 2025 was $763000.0 at Aclaris Therapeutics, down from $2.8 million in the prior quarter.
  • Over the last five years, Gross Profit for ACRS hit a ceiling of $18.1 million in Q3 2022 and a floor of $298000.0 in Q1 2022.
  • Median Gross Profit over the past 5 years was $1.4 million (2024), compared with a mean of $3.9 million.
  • Biggest five-year swings in Gross Profit: skyrocketed 3131.25% in 2022 and later crashed 91.03% in 2025.
  • Aclaris Therapeutics' Gross Profit stood at $352000.0 in 2021, then skyrocketed by 1853.41% to $6.9 million in 2022, then skyrocketed by 144.98% to $16.8 million in 2023, then plummeted by 49.5% to $8.5 million in 2024, then crashed by 91.03% to $763000.0 in 2025.
  • The last three reported values for Gross Profit were $763000.0 (Q4 2025), $2.8 million (Q3 2025), and $1.3 million (Q2 2025) per Business Quant data.